Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
29 November 2022 | Story Leonie Bolleurs | Photo Leonie Bolleurs
UFS green concrete
The Department of Engineering Sciences (EnSci) welcomes collaborations with other departments at the UFS. Pictured here are, from the left: Louis Lagrange, Head of EnSci, Prof Kahilu Kajimo-Shakantu, Head of the Department of Quantity Surveying and Construction Management, Dr Abdolhossein Naghizadeh, and Megan Welman-Purchase, analytical scientist in the Department of Geology.

More than 30 million tonnes of fly ash (residue from coal combustion in power plants) are generated in South Africa annually, with 96% of that being disposed of in landfills. There is thus more than enough of this key ingredient to produce green concrete. 

Green concrete, so called due to its environmentally friendly benefits, is an eco-friendly alternative to conventional concrete based on the Portland cement binder. During the production of green concrete, less carbon dioxide is released into the atmosphere than with the production of ordinary Portland cement (OPC). The latter accounts for up to 8% of all global carbon emissions.

Successful tests

In the Green Concrete Lab, established in 2021 within the Department of Engineering Sciences (EnSci) on the Bloemfontein Campus of the University of the Free State (UFS), Dr Abdolhossein Naghizadeh, Senior Lecturer, researcher, and engineer, is working on green cement and concrete projects.

He uses ‘geopolymer’ technology and a mix of waste materials, alkaline solutions, and recycled aggregates to form concrete mixtures that can provide properties similar to conventional concrete.

Besides being a synthesised inorganic material (not a petrochemical product), the geopolymer cement he introduced has the following properties: it is made from a reaction between aluminosilicate materials and strong alkalis (5-7% of the concrete mixture), it uses water and by-products as raw materials, it does not calcinate lime, thus giving it a low carbon emission, and it is also beneficial from a waste management point of view. 

The waste materials used can include waste from industrial and agricultural sources, such as fly ash, rice husk ash, sugar-cane bagasse, or corncob ash, as well as natural materials such as volcanic ash. In South Africa, sufficient amounts of industrial and agricultural waste are available. 

“So far, we have successfully tested various types of green concrete based on different waste materials,” says Dr Naghizadeh. 

Besides researching the green mixture proportions in the lab, Dr Naghizadeh and his students focused their attention on establishing the strength, durability, workability, and production cost of the product. 

They compared green concrete with conventional concrete. Green concrete’s workability is slightly lower (but he believes that with appropriate mix design it can be corrected), and it has a much higher compressive strength (50-90 MPa), a smaller carbon footprint, and comparable production costs to conventional concrete (depending on the mix design). A very high level of resistance against alkali-silica reaction (concrete cancer) is also present, as well as resistance to carbonation, sulphate attack, and acid attack.
So far, we have successfully tested various types of green concrete based on different waste materials.– Dr Naghizadeh. 

He explains, “The superior durability performance of green concrete is related to its chemical compositions and microstructure. For example, the lack of calcium content in the composition provides better resistance to alkali-silica reaction. At the same time, stronger bonds between elements and polymeric microstructure provide better resistance against acids and fire.”

With all the work and research of the past year and a half, Dr Naghizadeh says they are at the stage where they can prescribe green concrete production recipes for the industry parties based on the specified application and the materials they have.

Biggest accomplishments

“We transferred most of the experimental works to the Green Concrete Lab at the beginning of 2022, which improved our productivity tremendously. Since then, nine journal papers and three peer-reviewed conference papers have been published as outputs of the research projects. Currently, there are also multiple publications under review or in the development stages,” says Dr Naghizadeh.

In addition to him, there are three master's students and one research associate working on their own individual projects.

The department is very proud of its research outputs. Dr Naghizadeh was either author or co-author of all 12 research papers. The focus of these papers was mostly on the formulation of green concrete, based on locally available agricultural waste materials, the formulation of one-part geopolymer cement (when aluminosilicate raw material is replaced with pre-activated aluminosilicate material, water can be used instead of alkali solution), and the development of ambient-cured green concrete (replacing the aluminosilicate raw material with a blend of materials).

Dr Naghizadeh is also the project leader of a group of scientists from local and international universities who are researching sustainable construction materials. These institutions include the Universities of Johannesburg, KwaZulu-Natal, Yaoundé in Cameroon, Erzurum Technical University in Turkey, as well as Nelson Mandela University and the Central University of Technology, which recently came on board. 

 


 


News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept